Experts discuss the transition from biologics to biosimilars and emphasize the importance of adaptability when non-medical switching occurs.
EP. 1: Utilizing Recently Approved Biosimilars in Clinical Practice
Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.
EP. 2: Transitioning to Biosimilars: Considerations for Providers and Payers
Panelists explore opportunities for biosimilars to manage inflammatory conditions.
EP. 3: Navigating Challenges Associated with Biosimilars Across Various Disease States
Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.
EP. 4: Provider Acceptance Driving Confidence in Biosimilar Therapy
Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.
EP. 5: Decision-Making Process Surrounding Biosimilar Implementation
Experts compare approaches to prescribing biosimilars over reference drugs.
EP. 6: Biosimilar Administration Considerations Impacting Patient Experience
Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications.
EP. 7: Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience
Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.
EP. 8: Switching Patients from Reference Product to Biosimilar
Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.
EP. 9: Defining Interchangeability and Switching in Biologics
Medical experts discuss interchangeability designation requirements for biosimilars.
EP. 10: Evolution of Auto-Substitution in Biosimilar Landscape
Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.
EP. 11: An Overview of Biosimilar Extrapolation During FDA Approval
Specialists define and discuss extrapolation, along with the importance of strong data in specific disease states.
EP. 12: Harnessing Indication-Specific Data on Biosimilars
Professionals explore the importance of indication-specific data in gastroenterology.
2 Clarke Drive Cranbury, NJ 08512